Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests
Executive Summary
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
You may also be interested in...
Drug Pricing Reform In Medicaid: Watch This Space
Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden.
Calls For National Tech Assessment Program Could Be Amplified By Costs Of Cell, Gene Therapy
Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.
Playing The Trump Card On Rx Pricing
Obamacare repeal has been replaced by rebrand as Trump administration plans to use ACA’s Medicare demonstration powers to send discount cards to seniors, one of a slew of health care announcements that include Rx importation, pre-existing conditions, insulin and EpiPens.